179 related articles for article (PubMed ID: 38243011)
1. Comparison of the ADNEX and ROMA risk prediction models for the diagnosis of ovarian cancer: a multicentre external validation in patients who underwent surgery.
Landolfo C; Ceusters J; Valentin L; Froyman W; Van Gorp T; Heremans R; Baert T; Wouters R; Vankerckhoven A; Van Rompuy AS; Billen J; Moro F; Mascilini F; Neumann A; Van Holsbeke C; Chiappa V; Bourne T; Fischerova D; Testa A; Coosemans A; Timmerman D; Van Calster B
Br J Cancer; 2024 Apr; 130(6):934-940. PubMed ID: 38243011
[TBL] [Abstract][Full Text] [Related]
2. Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort study.
Van Calster B; Valentin L; Froyman W; Landolfo C; Ceusters J; Testa AC; Wynants L; Sladkevicius P; Van Holsbeke C; Domali E; Fruscio R; Epstein E; Franchi D; Kudla MJ; Chiappa V; Alcazar JL; Leone FPG; Buonomo F; Coccia ME; Guerriero S; Deo N; Jokubkiene L; Savelli L; Fischerová D; Czekierdowski A; Kaijser J; Coosemans A; Scambia G; Vergote I; Bourne T; Timmerman D
BMJ; 2020 Jul; 370():m2614. PubMed ID: 32732303
[TBL] [Abstract][Full Text] [Related]
3. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China.
Chen H; Qian L; Jiang M; Du Q; Yuan F; Feng W
Ultrasound Obstet Gynecol; 2019 Dec; 54(6):815-822. PubMed ID: 31152572
[TBL] [Abstract][Full Text] [Related]
4. Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods.
Meys EMJ; Jeelof LS; Achten NMJ; Slangen BFM; Lambrechts S; Kruitwagen RFPM; Van Gorp T
Ultrasound Obstet Gynecol; 2017 Jun; 49(6):784-792. PubMed ID: 27514486
[TBL] [Abstract][Full Text] [Related]
5. Performance of IOTA Simple Rules, Simple Rules risk assessment, ADNEX model and O-RADS in differentiating between benign and malignant adnexal lesions in North American women.
Hiett AK; Sonek JD; Guy M; Reid TJ
Ultrasound Obstet Gynecol; 2022 May; 59(5):668-676. PubMed ID: 34533862
[TBL] [Abstract][Full Text] [Related]
6. Estimating the risk of malignancy of adnexal masses: validation of the ADNEX model in the hands of nonexpert ultrasonographers in a gynaecological oncology centre in China.
He P; Wang JJ; Duan W; Song C; Yang Y; Wu QQ
J Ovarian Res; 2021 Dec; 14(1):169. PubMed ID: 34857005
[TBL] [Abstract][Full Text] [Related]
7. Prospective external validation of IOTA methods for classifying adnexal masses and retrospective assessment of two-step strategy using benign descriptors and ADNEX: a Portuguese multicenter study.
Borges AL; Brito M; Ambrósio P; Condeço R; Pinto P; Ambrósio B; Mahomed F; Gama JMR; Bernardo MJ; Gouveia AI; Djokovic D
Ultrasound Obstet Gynecol; 2024 Mar; ():. PubMed ID: 38477149
[TBL] [Abstract][Full Text] [Related]
8. Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women.
Davenport C; Rai N; Sharma P; Deeks JJ; Berhane S; Mallett S; Saha P; Champaneria R; Bayliss SE; Snell KI; Sundar S
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD011964. PubMed ID: 35879201
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Performance of Ultrasonography-Based Risk Models in Differentiating Between Benign and Malignant Ovarian Tumors in a US Cohort.
Yoeli-Bik R; Longman RE; Wroblewski K; Weigert M; Abramowicz JS; Lengyel E
JAMA Netw Open; 2023 Jul; 6(7):e2323289. PubMed ID: 37440228
[TBL] [Abstract][Full Text] [Related]
10. Benign descriptors and ADNEX in two-step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort.
Landolfo C; Bourne T; Froyman W; Van Calster B; Ceusters J; Testa AC; Wynants L; Sladkevicius P; Van Holsbeke C; Domali E; Fruscio R; Epstein E; Franchi D; Kudla MJ; Chiappa V; Alcazar JL; Leone FPG; Buonomo F; Coccia ME; Guerriero S; Deo N; Jokubkiene L; Savelli L; Fischerova D; Czekierdowski A; Kaijser J; Coosemans A; Scambia G; Vergote I; Timmerman D; Valentin L
Ultrasound Obstet Gynecol; 2023 Feb; 61(2):231-242. PubMed ID: 36178788
[TBL] [Abstract][Full Text] [Related]
11. Subjective assessment and IOTA ADNEX model in evaluation of adnexal masses in patients with history of breast cancer.
Pozzati F; Sassu CM; Marini G; Mascilini F; Biscione A; Giannarelli D; Garganese G; Fragomeni SM; Scambia G; Testa AC; Moro F
Ultrasound Obstet Gynecol; 2023 Oct; 62(4):594-602. PubMed ID: 37204769
[TBL] [Abstract][Full Text] [Related]
12. Performance of IOTA Simple Rules Risks, ADNEX Model, Subjective Assessment Compared to CA125 and HE4 with ROMA Algorithm in Discriminating between Benign, Borderline and Stage I Malignant Adnexal Lesions.
Czekierdowski A; Stachowicz N; Smolen A; Łoziński T; Guzik P; Kluz T
Diagnostics (Basel); 2023 Feb; 13(5):. PubMed ID: 36900029
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study.
Van Calster B; Van Hoorde K; Valentin L; Testa AC; Fischerova D; Van Holsbeke C; Savelli L; Franchi D; Epstein E; Kaijser J; Van Belle V; Czekierdowski A; Guerriero S; Fruscio R; Lanzani C; Scala F; Bourne T; Timmerman D;
BMJ; 2014 Oct; 349():g5920. PubMed ID: 25320247
[TBL] [Abstract][Full Text] [Related]
14. Validation of ADNEX and IOTA two-step strategy and estimation of risk of complications during follow-up of adnexal masses in low-risk population.
Pascual MA; Vancraeynest L; Timmerman S; Ceusters J; Ledger A; Graupera B; Rodriguez I; Valero B; Landolfo C; Testa AC; Bourne T; Timmerman D; Valentin L; Van Calster B; Froyman W
Ultrasound Obstet Gynecol; 2024 Mar; ():. PubMed ID: 38477179
[TBL] [Abstract][Full Text] [Related]
15. The ADNEX model to triage adnexal masses: An external validation study and comparison with the IOTA two-step strategy and subjective assessment by an experienced ultrasound operator.
Viora E; Piovano E; Baima Poma C; Cotrino I; Castiglione A; Cavallero C; Sciarrone A; Bastonero S; Iskra L; Zola P
Eur J Obstet Gynecol Reprod Biol; 2020 Apr; 247():207-211. PubMed ID: 32146226
[TBL] [Abstract][Full Text] [Related]
16. Clinical Utility of Risk Models to Refer Patients with Adnexal Masses to Specialized Oncology Care: Multicenter External Validation Using Decision Curve Analysis.
Wynants L; Timmerman D; Verbakel JY; Testa A; Savelli L; Fischerova D; Franchi D; Van Holsbeke C; Epstein E; Froyman W; Guerriero S; Rossi A; Fruscio R; Leone FP; Bourne T; Valentin L; Van Calster B
Clin Cancer Res; 2017 Sep; 23(17):5082-5090. PubMed ID: 28512173
[No Abstract] [Full Text] [Related]
17. Reliability of IOTA score and ADNEX model in the screening of ovarian malignancy in postmenopausal women.
Nohuz E; De Simone L; Chêne G
J Gynecol Obstet Hum Reprod; 2019 Feb; 48(2):103-107. PubMed ID: 29709594
[TBL] [Abstract][Full Text] [Related]
18. Performance of the IOTA ADNEX model in preoperative discrimination of adnexal masses in a gynecological oncology center.
Araujo KG; Jales RM; Pereira PN; Yoshida A; de Angelo Andrade L; Sarian LO; Derchain S
Ultrasound Obstet Gynecol; 2017 Jun; 49(6):778-783. PubMed ID: 27194129
[TBL] [Abstract][Full Text] [Related]
19. External Validation of the Assessment of Different NEoplasias in the adneXa Model Performance in Evaluating the Risk of Ovarian Carcinoma Before Surgery in China: A Tertiary Center Study.
Zhang Y; Zhao Y; Feng L
J Ultrasound Med; 2022 Sep; 41(9):2333-2342. PubMed ID: 34918371
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the O-RADS and ADNEX models regarding malignancy rate and validity in evaluating adnexal lesions.
Chen GY; Hsu TF; Chan IS; Liu CH; Chao WT; Shih YC; Jiang LY; Chang YH; Wang PH; Chen YJ
Eur Radiol; 2022 Nov; 32(11):7854-7864. PubMed ID: 35583711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
